TECHNESCAN PYP 20MG Kit pro radiofarmakum Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

technescan pyp 20mg kit pro radiofarmakum

curium netherlands b.v., petten array - 11542 dekahydrÁt difosforeČnanu sodnÉho; 3122 dihydrÁt chloridu cÍnatÉho - kit pro radiofarmakum - 20mg - technecium-(99mtc) sn2+ Činidla, pro znaČenÍ bunĚk

BRAIN-SPECT KIT 0,3MG Kit pro radiofarmakum Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

brain-spect kit 0,3mg kit pro radiofarmakum

medi-radiopharma kft., Érd array - 10334 exametazim - kit pro radiofarmakum - 0,3mg - technecium-(99mtc) exametazim

CARDIO-SPECT 0,5MG Kit pro radiofarmakum Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

cardio-spect 0,5mg kit pro radiofarmakum

medi-radiopharma kft., Érd array - 10321 tetrafluoroboritan tetramibimĚĎnÝ - kit pro radiofarmakum - 0,5mg - technecium-(99mtc) sestamibi

EXAMETAZIM RADIOPHARMACY LABORATORIUM 500MCG Kit pro radiofarmakum Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

exametazim radiopharmacy laboratorium 500mcg kit pro radiofarmakum

radiopharmacy laboratorium kft., budaörs array - 10334 exametazim - kit pro radiofarmakum - 500mcg - technecium-(99mtc) exametazim

PEROXID VODÍKU FAGRON 3% Kožní sprej, roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

peroxid vodíku fagron 3% kožní sprej, roztok

fagron a.s., olomouc array - 2913 peroxid vodÍku 30% - kožní sprej, roztok - 3% - peroxid vodÍku

Dimethyl fumarate Neuraxpharm Evropská unie - čeština - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

LEUCO-SCINT 0,18MG Kit pro radiofarmakum Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

leuco-scint 0,18mg kit pro radiofarmakum

medi-radiopharma kft., Érd array - 10334 exametazim - kit pro radiofarmakum - 0,18mg - technecium-(99mtc) exametazim, pro znaČenÍ bunĚk

Suiseng Coli/C Injekční suspenze Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

suiseng coli/c injekční suspenze

laboratorios hipra s.a. - escherichia vakcína + clostridium vakcíny - injekční suspenze - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - prasata

Comirnaty Evropská unie - čeština - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použití této vakcíny musí být v souladu s oficiálními doporučeními.

Sapropterin Dipharma Evropská unie - čeština - EMA (European Medicines Agency)

sapropterin dipharma

dipharma arzneimittel gmbh - sapropterin-dihydrochloridu - fenylketonurie - jiné zažívací trakt a produkty metabolismu, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.